The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
AI Dermatology Mobile Apps Have Critical Efficacy, Safety Gaps, Review Says
March 17th 2024This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.
Read More
Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa
March 11th 2024Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Read More
Management of HS Requires Both Coordination, Communication Between Patients and Providers
March 10th 2024Treating pediatric and adult patients with hidradenitis suppurativa (HS) who are in socioeconomically underserved areas can be done through collaboration with the patient, their family, and other clinicians in the field.
Read More
Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors
March 8th 2024There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.
Watch
Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments
March 8th 2024A physician-reported outcomes survey found that physicians switched to ruxolitinib cream due to lack of effectiveness with previous atopic dermatitis (AD) treatments, and an analysis of claims data revealed the cream reduced the need for other treatments.
Read More
FDA Grants Accelerated Approval to Lifileucel, First Cellular Therapy for Advanced Melanoma
February 16th 2024Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.
Read More
What We’re Reading: Inflation Penalties; Melanoma Vaccine; Respiratory Vaccine Coverage
December 15th 2023A vaccine is showing promising results in treating melanoma; the Biden administration will implement inflation penalties on dozens of drugmakers to reduce out-of-pocket costs for Medicare recipients; the CDC issued an alert urging health care providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV).
Read More
Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials
November 15th 2023Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.
Read More
Darker Skin Means Different Presentations of Skin Diseases, Explains Dr James Song
October 23rd 2023Recognizing that skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa present differently in skin of color can prevent delays in diagnosis and treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.
Read More